Estrella Immunopharma (NASDAQ:ESLA) Given “Buy” Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Estrella Immunopharma (NASDAQ:ESLA) in a research note published on Monday,Benzinga reports. D. Boral Capital currently has a $16.00 price objective on the stock.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Estrella Immunopharma in a research note on Friday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $16.00.

Estrella Immunopharma Trading Up 26.0%

Shares of Estrella Immunopharma stock opened at $3.05 on Monday. The company’s fifty day simple moving average is $1.46 and its 200-day simple moving average is $1.13. The company has a market cap of $113.06 million, a price-to-earnings ratio of -10.17 and a beta of 0.51. Estrella Immunopharma has a 1 year low of $0.70 and a 1 year high of $3.09.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.